肿瘤细胞治疗研究
英文原题：Hattrick against Lymphoma with Trispecific CAR T Cells.
Vasu 及其同事报告了靶向 CD19、CD20 和 CD22 的快速制备三特异性CAR-T 细胞的首批临床评估之一。
Vasu及其同事报告了快速制备、靶向CD19、CD20和CD22的三特异性CAR-T 细胞首次临床评估之一。观察到的淋巴瘤疗效信号和良好安全性支持进一步研究；相关性分析则提示，治疗前T细胞的适应状态以及输注后早期的功能状态，可能仍是影响疗效的重要因素。相关研究见Vasu等发表于第711页的文章。
Vasu and colleagues report one of the first clinical evaluations of rapidly manufactured trispecific chimeric antigen receptor T cells targeting CD19, CD20, and CD22. The lymphoma efficacy signal and favorable observed safety profile support further investigation, whereas the correlative analyses suggest that baseline T-cell fitness and early post-infusion functional states may remain important determinants of outcome. See related article by Vasu et al., p. 711.
MEMBER ACCOUNT
登录成功会直接打开下一页。
